Cell and Gene Therapy Manufacturing Market
Cell and Gene Therapy Manufacturing Market - Global Industry Assessment & Forecast
#
Pages:
141
2022
Jul - 2023
VMR-2227
Segments Covered
By
Type Cell Therapy, Gene Therapy
-
By
Indication Oncology Diseases, Inherited Disorders, Cardiovascular Diseases, Musculoskeletal Disorders, Neurological Diseases, Other Indications
-
By
Application Clinical Manufacturing, Commercial Manufacturing
-
By
End User Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organizations (CMOs), Research Institutes & Academic Centers, Regulatory Agencies, Other End Users
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 4.8 Billion |
 Revenue 2030:
|
USD 15.4 Billion |
 Revenue CAGR
(2023 - 2030): |
18.2% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2017 to 2021 |
| 3. | Forecast Data | 2023 to 2030 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
Vantage Market
Research | 01-Aug-2023
FAQ
Frequently Asked Question
What is the global demand for Cell and Gene Therapy Manufacturing in terms of revenue?
-
The global Cell and Gene Therapy Manufacturing valued at USD 4.8 Billion in 2022 and is expected to reach USD 15.4 Billion in 2030 growing at a CAGR of 18.2%.
Which are the prominent players in the market?
-
The prominent players in the market are Lonza (Switzerland), Bluebird Bio (U.S.), Catalent Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Samsung Biologics (South Korea), Boehringer Ingelheim (Germany), Cellular Therapeutics (China), Hitachi Chemical Co. Ltd. (Japan), Takara Bio Inc. (Japan), Miltenyi Biotec (U.S.), Thermo Fisher Scientific (U.S.), Novartis International AG (Switzerland), Merck KGaA (Germany), Wuxi Advanced Therapies (U.S.), Fujifilm Holdings Corp. (Japan), Charles River Laboratories International Inc. (U.S.), GE Healthcare Life Sciences (U.S.), CGT Catapult (UK), CoJourney Inc. (China), ElevateBio LLC (U.S.), Pfizer Inc. (U.S.), Incyte Corp. (U.S.), AllogeneTherapeutics Inc. (U.S.).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 18.2% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Cell and Gene Therapy Manufacturing include
- High incidence of cancer and other target diseases
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Cell and Gene Therapy Manufacturing in 2022.
